Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.
about
HIV Genome-Wide Protein Associations: a Review of 30 Years of ResearchAlternative coreceptor requirements for efficient CCR5- and CXCR4-mediated HIV-1 entry into macrophages.Differential use of CCR5 by HIV-1 clinical isolates resistant to small-molecule CCR5 antagonists.HIV-1 resistance to maraviroc conferred by a CD4 binding site mutation in the envelope glycoprotein gp120Development of Small-molecule HIV Entry Inhibitors Specifically Targeting gp120 or gp41A common mechanism of clinical HIV-1 resistance to the CCR5 antagonist maraviroc despite divergent resistance levels and lack of common gp120 resistance mutationsThe evolution of drug resistance interpretation algorithms: ANRS, REGA and extension of resistance analysis to HIV-1 group O and HIV-2.Escape from human immunodeficiency virus type 1 (HIV-1) entry inhibitors.Statistical correlation of nonconservative substitutions of HIV gp41 variable amino acid residues with the R5X4 HIV-1 phenotype.Resistance of human immunodeficiency virus type 1 to a third-generation fusion inhibitor requires multiple mutations in gp41 and is accompanied by a dramatic loss of gp41 functionAdaptation of HIV-1 to cells with low expression of the CCR5 coreceptor.Effects of sequence changes in the HIV-1 gp41 fusion peptide on CCR5 inhibitor resistance.Env-glycoprotein heterogeneity as a source of apparent synergy and enhanced cooperativity in inhibition of HIV-1 infection by neutralizing antibodies and entry inhibitorsMultiple CCR5 conformations on the cell surface are used differentially by human immunodeficiency viruses resistant or sensitive to CCR5 inhibitors.Open and closed structures reveal allostery and pliability in the HIV-1 envelope spike.
P2860
Q26746070-CB8093B8-D1F7-49DC-B28B-92ACF925E060Q35274763-792B971F-B1F1-456A-9153-F5EFC5E60366Q35867443-A2586902-5B6B-4139-B183-E6D092A2C041Q36559608-EA783938-64C4-4B76-A65A-78A4AEDCFA8DQ36643050-61B82FAF-982F-4F20-B5F5-AC33D9E893E0Q36827946-F96C25B4-14E9-4EC4-8941-A7C0D4B25A97Q37979703-9934CFFC-FA47-4BA1-9E46-98CD4FA016F4Q38076139-9C146537-25B6-4713-95C1-DDE55DE10882Q38485666-AA7B1680-8F00-493B-BFFE-FBC77EB6D955Q38632078-E6007D0D-3BCD-4C13-B040-A4685A36E03AQ38703060-9480E087-A0AA-43B5-B2AD-BDB087AFFC63Q39361526-DE1123BB-FB6F-4D3E-8C7B-3137083DC8D5Q39454698-0A1B1445-95C0-483D-826F-5A1CB65C0B1FQ39523186-E22BA7F6-35B2-41D1-ADA5-9D95B4643381Q40125807-91761D2C-5C22-4693-960E-677DB14B3D19
P2860
Resistance of a human immunodeficiency virus type 1 isolate to a small molecule CCR5 inhibitor can involve sequence changes in both gp120 and gp41.
description
2011 nî lūn-bûn
@nan
2011年の論文
@ja
2011年論文
@yue
2011年論文
@zh-hant
2011年論文
@zh-hk
2011年論文
@zh-mo
2011年論文
@zh-tw
2011年论文
@wuu
2011年论文
@zh
2011年论文
@zh-cn
name
Resistance of a human immunode ...... hanges in both gp120 and gp41.
@en
type
label
Resistance of a human immunode ...... hanges in both gp120 and gp41.
@en
prefLabel
Resistance of a human immunode ...... hanges in both gp120 and gp41.
@en
P2093
P2860
P1433
P1476
Resistance of a human immunode ...... hanges in both gp120 and gp41.
@en
P2093
Antonia M Thomas
Cleo G Anastassopoulou
John P Moore
Per Johan Klasse
Rafael S Depetris
Thomas J Ketas
P2860
P356
10.1016/J.VIROL.2010.12.052
P407
P577
2011-02-26T00:00:00Z